CSM Corbion NV

Corbion reports the progress of its € 20 million share buyback program 20 May – 24 May 2024

Corbion reports the progress of its € 20 million share buyback program 20 May – 24 May 2024

Corbion hereby reports the transaction details related to its € 20 million share buyback program announced on 26 April 2024.

During the week of 20 May up to and including 24 May 2024 a total of 70,111 shares were repurchased at an average price of €20.7635 for a total amount of €1,455,751.78.

To date, the total consideration for shares repurchased amounts to €6,304,382.81 representing 31.52% of the overall share buyback program.

Corbion publishes on a weekly basis every Monday, an overview of the progress of the share buyback program on its website:

This overview contains detailed information on the daily amount of repurchased shares and individual share purchase transactions.

Attachment



EN
27/05/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Corbion NV

 PRESS RELEASE

Corbion published agenda for AGM

Corbion published agenda for AGM Corbion has published its agenda for the upcoming Annual General Meeting of Shareholders (AGM) to be held on 13 May 2026. The full AGM agenda together with explanatory notes is available on Corbion's under Investor relations --> Shareholder information --> Shareholder meetings. Attachment

Reg Watson ... (+2)
  • Reg Watson
  • CFA

Corbion/Goldilocks scenario extends/HOLD

Since our 12-month target price upgrade to €18.60 and change in recommendation from Sell to HOLD on 17 November 2025, Corbion has delivered its Capital Markets Day and full year results. Corbion confirmed at its 2025 results that the company had taken advantage of the low sugar price to hedge all its exposure for 2026 and 75% for 2027. This extends the Goldilocks scenario of lower costs and higher revenues from 2026 into 2027 and supports approximately half of the company's guided adj. EBITDA ma...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch